Bertrand Jean-Claude (Benoît Thibault, Benoit Thibault)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 6

Top Venues

Cancers

EMBO molecular medicine

Journal of ovarian research

International journal of molecular sciences

Centre de Recherche en Cancérologie de Toulouse, INSERM

Université Paul Sabatier (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Centre de Recherche en Cancérologie de Toulouse, INSERM

France

Postdoctoral Researcher :: SIGDYN Group - PI3K isoforms, Signalling & Cancerogenesis

McGill University

Canada

Postdoctoral Researcher :: Cancer Drug Research Laboratory

Institut Universitaire du Cancer Toulouse Oncopole

France

Postdoctoral Researcher :: EA 4553 - Individualization of ovarian and head and neck cancer treatment

Institut Claudius Regaud

France

Postdoctoral Researcher :: EA 4553, Individualization of ovarian and head and neck cancer treatment

Institut Claudius Regaud

France

PhD Student :: EA 4553, Individualization of ovarian and head and neck cancer treatment

Institut Claudius Regaud

France

Master of Sciences 2nd year Trainee :: EA3035 - Laboratory of experimental clinical pharmacology of anticancer drugs

Institut de Pharmacologie et de Biologie Structurale

France

Master of Sciences 1st year Trainee :: Differentiation and activation of phagocytes team

Education History

Université Paul Sabatier

France

PHD

Université Paul Sabatier

France

MSC

Publications

Bertrand Jean-Claude, Fernanda Ramos-Delgado, Julie Guillermet-Guibert
Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research. Cancers 15 (3) (2023)
Bertrand Jean-Claude, Fernanda Ramos-Delgado, Julie Guillermet-Guibert
Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research. Cancers 15 (3) (2023)
Suman Rao, Bertrand Jean-Claude, Lisa Peyrard, Anne-Laure Larroque-Lombard, Martin Rupp, Cédric Thauvin, Bertrand J Jean-Claude
Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting. International journal of molecular sciences 22 (17) (2021)
Bertrand Jean-Claude, Fernanda Ramos-Delgado, Elvire Pons-Tostivint, Nicole Therville, Celia Cintas, Silvia Arcucci, Stephanie Cassant-Sourdy, Gabriela Reyes-Castellanos, Marie Tosolini, Amelie V Villard, Coralie Cayron, Romain Baer, Justine Bertrand-Michel, Delphine Pagan, Dina Ferreira Da Mota, Hongkai Yan, Chiara Falcomatà, Fabrice Muscari, Barbara Bournet, Jean-Pierre Delord, Ezra Aksoy, Alice Carrier, Pierre Cordelier, Dieter Saur, Celine Basset, Julie Guillermet-Guibert
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. EMBO molecular medicine 13 (7) (2021)
Célia Cintas, Thibault Douche, Nicole Therville, Silvia Arcucci, Fernanda Ramos-Delgado, Céline Basset, Bertrand Jean-Claude, Julie Guillermet-Guibert
Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers 10 (6) (2018)
Benoît Thibault, Bertrand Jean-Claude
Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. Journal of ovarian research 10 (1) (2017)

Bertrand Jean-Claude.css-eqlu8i{font-size:small;padding-left:4px;} (Benoît Thibault, Benoit Thibault)

Publication Activity (10 Years)

Top Topics

Top Venues

Bertrand Jean-Claude (Benoît Thibault, Benoit Thibault)